Literature DB >> 17225050

Erythema multiforme and Stevens-Johnson syndrome following radiotherapy.

Tadamasa Yoshitake1, Katsumasa Nakamura, Yoshiyuki Shioyama, Tomonari Sasaki, Saiji Ooga, Madoka Abe, Yusuke Urashima, Kazunori Urabe, Hiromi Terashima, Hiroshi Honda.   

Abstract

Erythema multiforme (EM) and Stevens-Johnson syndrome (SJS) are thought to be hypersensitivity syndromes with various causes, and radiotherapy might be one of the causes of these syndromes. We herein report two cases of EM/SJS following radiotherapy. The first case was a 63-year-old woman with breast cancer. At the end of postoperative radiotherapy with 60 Gy, severe pruritic erythema appeared in the irradiated area and spread over the whole body. She was diagnosed with EM by a skin biopsy. The second case was a 77-year-old woman with uterine cervical cancer who underwent postoperative radiotherapy. At a dose of 30.6 Gy, pruritic redness appeared in the irradiated area and the precordial region, and it became widespread rapidly with polymorphic transformation. Although without any histological confirmation, SJS was strongly suspected because of her pruritic conjunctivitis. Because both patients were given medicines during irradiation, radiotherapy may not be the only cause of EM/SJS. However, it should be noted that radiotherapy might trigger EM/SJS.

Entities:  

Mesh:

Year:  2007        PMID: 17225050     DOI: 10.1007/s11604-006-0093-3

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  15 in total

1.  Radiation-induced erythema nodosum.

Authors:  S Takagawa; S Nakamura; H Yokozeki; K Nishioka
Journal:  Br J Dermatol       Date:  1999-02       Impact factor: 9.302

2.  Two cases of Stevens-Johnson syndrome: toxic epidermal necrolysis possibly induced by amifostine during radiotherapy.

Authors:  I Lale Atahan; E Ozyar; S Sahin; F Yildiz; B Yalçin; A Karaduman
Journal:  Br J Dermatol       Date:  2000-11       Impact factor: 9.302

Review 3.  Skin reactions to radiotherapy--a spectrum resembling erythema multiforme: case report and review of the literature.

Authors:  A B Fleischer; D I Rosenthal; S A Bernard; E J O'Keefe
Journal:  Cutis       Date:  1992-01

4.  Erythema multiforme: report of two cases and speculation on immune mechanisms involved in the pathogenesis.

Authors:  B Safai; R A Good; N K Day
Journal:  Clin Immunol Immunopathol       Date:  1977-05

5.  Severe erythema multiforme (Stevens-Johnson syndrome) following telecobalt therapy.

Authors:  P L Nawalkha; N K Mathur; Y K Malhotra; H C Saksena
Journal:  Br J Radiol       Date:  1972-10       Impact factor: 3.039

6.  Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy.

Authors:  Y M Khafaga; A Jamshed; A A Allam; W A Mourad; A Ezzat; A Al Eisa; A J Gray; H Schultz
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

Review 7.  Erythema multiforme (Stevens-Johnson syndrome) following deep radiation therapy.

Authors:  H B Ridgway; D J Miech
Journal:  Cutis       Date:  1993-06

8.  Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider.

Authors:  David Aguiar; Roberto Pazo; Ignacio Durán; Josefa Terrasa; Antonio Arrivi; Herminio Manzano; Javier Martín; Julio Rifá
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

9.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01

10.  Sweet's syndrome in a patient with oral cancer associated with radiotherapy.

Authors:  E H van der Meij; J B Epstein; J Hay; V Ho; K Lerner
Journal:  Eur J Cancer B Oral Oncol       Date:  1996-03
View more
  1 in total

1.  Stevens Johnson Syndrome in a patient undergoing gynaecological brachytherapy: An association or an incident?

Authors:  Miguel Reis Ferreira; Ana Amado; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2011-04-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.